EGFR and non-small cell lung carcinoma: Since 2004, several small molecules functioning as EGFR tyrosine kinase inhibitors (TKIs) have been approved by the FDA and other authorities as cancer therapies, particularly for the treatment of non-small cell lung cancer (NSCLC) (Table 1).